Medtronic's Expand URO study, the largest U.S. trial for robotic-assisted urologic surgery, showed that the Hugo RAS system met both safety and effectiveness goals. With a 98.5% surgical success rate and low complication rates, the study supports Hugo's FDA submission for urologic use. Data was shared at the AUA annual meeting in Las Vegas.